F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
29 mars 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021
16 mars 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Present at Upcoming Investor Conferences
04 mars 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
20 janv. 2021 08h00 HE
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics to Participate in Upcoming Conferences
06 janv. 2021 08h00 HE
|
F-star Therapeutics, Inc
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
04 janv. 2021 08h00 HE
|
F-star Therapeutics, Inc
FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company’s third bispecific to enter clinical trials Preclinical studies demonstrated potent...